Apixaban Again Tied to Lower GI Bleeding vs Other DOACs in Atrial Fibrillation
Gastrointestinal (GI) bleeds are about 20%–28% less likely in patients with atrial fibrillation (AF) taking apixaban (Eliquis) compared with other direct oral anticoagulants (DOACs), an observational study suggests. There were no differences between DOACs in risks for ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), or death.
The risk for GI bleeding was reduced for low-dose apixaban vs low-dose rivaroxaban (Xarelto), suggested the analysis of more than half a million patients with AF taking one of four DOACs for stroke prevention. The study also covered edoxaban (Lixiana) and dabigatran (Pradaxa).
The results were similar in a subgroup analysis for patients aged 80 and older and those with chronic kidney disease (CKD).
@yashitaa what was so compelling about this particular analysis was that it wasn't from just one dataset or one country. They had five datasets across 4 different countries